Stock Events

Enanta Pharmaceuticals 

€9.9
2
+€0+0% Friday 19:55

Statistics

Day High
10.1
Day Low
9.55
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
272.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

25
NOV
Earnings
 

Earnings

25NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-2.33
-1.91
-1.49
-1.07
Expected EPS
-1.160749
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9EP.F. It's not an investment recommendation.
Alphabet
73743
GOOGL
Apple
64319
AAPL
Microsoft
60017
MSFT
Amazon
55316
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences is a direct competitor in the antiviral drug market, particularly in treatments for hepatitis C, where Enanta and Gilead have had collaborations but also compete.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie competes with Enanta in the hepatitis C virus (HCV) treatment market, especially since Enanta has developed drugs that are part of AbbVie's HCV treatment regimens.
Merck
MRK
Mkt Cap300.25B
Merck & Co. is involved in developing treatments for infectious diseases, including hepatitis C, directly competing with Enanta's drug development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals competes with Enanta in the development of treatments for cystic fibrosis, as both companies are involved in creating therapies for genetic and chronic diseases.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb competes in the antiviral space, particularly in hepatitis B and C, areas where Enanta Pharmaceuticals has significant interest and development efforts.
Pfizer
PFE
Mkt Cap164.39B
Pfizer competes across a broad range of therapeutic areas, including antiviral drugs, which puts it in competition with Enanta Pharmaceuticals in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Enanta in the development of treatments for infectious diseases, including hepatitis C.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline competes with Enanta in the development of vaccines and treatments for viral infections, including hepatitis and respiratory diseases.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap2.96B
Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics for chronic diseases, including hepatitis B, making it a competitor in the viral infection treatment market.

Analyst Ratings

19.67€Average Price Target
The highest estimate is €27.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
33%
Sell
33%

About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
Dr. Jay R. Luly Ph.D.
Employees
145
Country
US
ISIN
US29251M1062
WKN
000A1T7BJ

Listings

F
DE
9EP.F
XNAS
US
ENTA